Genetic Digital Shortlisted for PM Society Digital Award for Epilepsy Meds App
July 22, 2025 | Digital Agency, Epilepsy, PM Society Awards, apps, genetic digital
Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds, a mobile-first app that helps healthcare professionals make safer, patient-specific prescribing decisions in epilepsy care. The app is endorsed by leading epilepsy organisations and used across the NHS.
Specialist pharma and life sciences digital agency Genetic Digital has been shortlisted in the 2025 PM Society Digital Awards for its work on Epilepsy Meds, a mobile-first clinical support app developed in partnership with Desitin Pharma and educational content specialists ChangeMed.
Shortlisted in the HCP Education, Training & Support category, the app responds to a critical challenge identified during multidisciplinary NHS advisory boards: the need for a single, trusted resource to compare anti-seizure medications by formulation, excipients, and patient suitability — particularly for children, the elderly, and those with swallowing difficulties.
“Epilepsy treatment is complex, and formulation choice plays a vital role in patient outcomes,” said Damon Lightley, Managing Director at Genetic Digital. “We set out to create an easy-to-use, ABPI-compliant tool that helps clinicians make safer, more confident decisions at the point of care.”
Built with UX precision and clinical collaboration, Epilepsy Meds allows users to search and filter over 570 products by attributes such as sugar-free, alcohol-free, and safety in pregnancy, with direct links to SPCs and visual product identifiers. In its first 12 months, the app recorded over 1,000 active users and more than 34,000 interactions, reflecting strong adoption within a niche specialist community.
The app has been endorsed by Young Epilepsy, Epilepsy Society, and Epilepsy Action, and is now in active use across NHS Trusts, alongside companion educational materials including a printed medicines booklet and poster.
Healthcare professionals have praised the app for its clarity, clinical relevance, and time-saving impact:
“This is a great resource for busy healthcare professionals… It bridges the gap between complex pharmaceutical data and practical, safe prescribing.”
— Steve Tomlin, Director, Children’s Medicines Research & Innovation Centre, Great Ormond Street Hospital“It’s quick, reliable, and gives me exactly what I need — especially when juggling complex cases in busy clinics.”
— Prof. Charlotte Lawthom, Consultant Neurologist, Aneurin Bevan University Health Board
The initiative has also enhanced Desitin’s reputation as a valued clinical partner, opening up more meaningful conversations with HCPs and positioning the company as a provider of trusted, non-promotional support tools in epilepsy care.
This content was provided by Genetic Digital
Company Details
Latest Content from Genetic Digital
Why pharma website projects stall long before compliance becomes the problem
Pharma teams often blame compliance when digital projects slow down. In reality, the bigger issue is usually weaker ownership, unclear review models and content structures that were never designed for...
EpilepsyMeds receives Highly Commended recognition at Excellence in Healthcare Partnership Awards 2026
EpilepsyMeds received Highly Commended recognition at the Excellence in Healthcare Partnership Awards 2026, celebrating the collaboration between Desitin Pharma, ChangeMed and Genetic Digital in advancing epilepsy care.
Genetic Digital Wins Silver at PM Society Digital Awards for Epilepsy Meds Clinical Support App
Genetic Digital wins Silver at the PM Society Digital Awards for Epilepsy Meds, a clinical support app developed with Desitin and ChangeMed to aid patient-specific prescribing in epilepsy care.
Genetic Digital Shortlisted for PM Society Digital Award for Epilepsy Meds App
Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds, a mobile-first app that helps healthcare professionals make safer, patient-specific prescribing decisions in epilepsy care. The...
Smarter, Compliant Engagement: Why Pharma is Warming Up to Chat-Based Solutions
Pharma marketers are embracing chat-based tools to engage HCPs and patients faster, simplify PI sharing, and gain real-time insights — all while staying ABPI and GDPR compliant. When aligned with...
Why Pharma’s Digital PI Compliance Problem Needs a Cross-Functional Fix
In many pharma teams, the responsibility for keeping prescribing information (PI) up to date online falls into a grey area. > Regulatory signs it off. > Marketing publishes it. >...
Web Design Strategies for Pharma & Life Sciences in 2025
As we approach 2025, healthcare and life sciences SMEs face an increasingly digital world. A seamless, mobile-friendly website that harnesses AI-driven personalisation and intuitive design elements isn’t just a luxury...
Leveraging the ABPI QR Code Update: Enhancing Prescribing Information Through Best Practices
ABPI's recent update permits QR codes in printed pharmaceutical materials for prescribing information. By ensuring visibility, providing clear instructions, linking directly, and keeping content current, companies can enhance accessibility, ensure...
Pi 360 – A Smarter, Automated Solution for Digital Prescribing Information (PI) & QR Code Compliance
Life sciences digital agency Genetic Digital has launched Pi 360, a cutting-edge web application designed to help pharmaceutical companies automate the creation, management and distribution of Prescribing Information (PI) while...
Hidden in Plain Sight: The Compliance Risks of Search Engine Indexed Pharma Content
Pharma companies must balance HCP access and MHRA/ABPI compliance by preventing public search indexing of promotional prescription medicine content.
- 1
- 2